Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based compensation expense	$ 600	$ 300	$ 1,381	$ 1,246
Performance-Based Options [Member]
Share-based compensation expense	$ 300
Stock Incentive Plan [Member]
Share-based compensation arrangement by share-based payment award, description			Stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units ("RSUs") granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.